Bypass Surgery Versus Endovascular Therapy in Chronic Hemodialysis Patients With CLI Due to Infrainguinal Disease

Yoshitaka Kumada; Hideki Ishii; Toru Aoyama; Daisuke Kamoi; Takashi Sakakibara; Norio Umemoto; Susumu Suzuki; Hiroshi Takahashi; Toyoaki Murohara

doi:10.1016/j.jacc.2016.07.736

Bypass Surgery Versus Endovascular Therapy in Chronic Hemodialysis Patients With CLI Due to Infrainguinal Disease

Yoshitaka Kumada
, Hideki Ishii
, Toru Aoyama
, Daisuke Kamoi
, Takashi Sakakibara
, Norio Umemoto
, Susumu Suzuki
, Hiroshi Takahashi
, Toyoaki Murohara

研究成果: ジャーナルへの寄稿 › Letter › 査読

本文言語	英語
ページ（範囲）	1601-1602
ページ数	2
ジャーナル	Journal of the American College of Cardiology
巻	68
号	14
DOI	https://doi.org/10.1016/j.jacc.2016.07.736
出版ステータス	出版済み - 04-10-2016

All Science Journal Classification (ASJC) codes

循環器および心血管医学

文献へのアクセス

10.1016/j.jacc.2016.07.736

他のファイルとリンク

引用スタイル

@article{1963a6278dfa4435b91d88272afbc9df,

title = "Bypass Surgery Versus Endovascular Therapy in Chronic Hemodialysis Patients With CLI Due to Infrainguinal Disease",

author = "Yoshitaka Kumada and Hideki Ishii and Toru Aoyama and Daisuke Kamoi and Takashi Sakakibara and Norio Umemoto and Susumu Suzuki and Hiroshi Takahashi and Toyoaki Murohara",

note = "Funding Information: Please note: Dr. Ishii has received lecture fees from Astellas Pharma, AstraZeneca, Daiichi-Sankyo Pharma, and MSD. Dr. Murohara has received lecture fees from Bayer Pharmaceutical, Daiichi-Sankyo, Dainippon Sumitomo Pharma, Kowa, MSD, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Novartis Pharma, Pfizer Japan, Sanofi, and Takeda Pharmaceutical; and unrestricted research grants for the Department of Cardiology, Nagoya University Graduate School of Medicine, from Astellas Pharma, Daiichi-Sankyo, Dainippon Sumitomo Pharma, Kowa, MSD, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Novartis Pharma, Otsuka Pharma, Pfizer Japan, Sanofi, Takeda Pharmaceutical, and Teijin Pharma. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",

year = "2016",

month = oct,

day = "4",

doi = "10.1016/j.jacc.2016.07.736",

language = "English",

volume = "68",

pages = "1601--1602",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier Inc.",

number = "14",

}

TY - JOUR

T1 - Bypass Surgery Versus Endovascular Therapy in Chronic Hemodialysis Patients With CLI Due to Infrainguinal Disease

AU - Kumada, Yoshitaka

AU - Ishii, Hideki

AU - Aoyama, Toru

AU - Kamoi, Daisuke

AU - Sakakibara, Takashi

AU - Umemoto, Norio

AU - Suzuki, Susumu

AU - Takahashi, Hiroshi

AU - Murohara, Toyoaki

N1 - Funding Information: Please note: Dr. Ishii has received lecture fees from Astellas Pharma, AstraZeneca, Daiichi-Sankyo Pharma, and MSD. Dr. Murohara has received lecture fees from Bayer Pharmaceutical, Daiichi-Sankyo, Dainippon Sumitomo Pharma, Kowa, MSD, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Novartis Pharma, Pfizer Japan, Sanofi, and Takeda Pharmaceutical; and unrestricted research grants for the Department of Cardiology, Nagoya University Graduate School of Medicine, from Astellas Pharma, Daiichi-Sankyo, Dainippon Sumitomo Pharma, Kowa, MSD, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Novartis Pharma, Otsuka Pharma, Pfizer Japan, Sanofi, Takeda Pharmaceutical, and Teijin Pharma. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2016/10/4

Y1 - 2016/10/4

UR - https://www.scopus.com/pages/publications/84992034596

UR - https://www.scopus.com/pages/publications/84992034596#tab=citedBy

U2 - 10.1016/j.jacc.2016.07.736

DO - 10.1016/j.jacc.2016.07.736

M3 - Letter

C2 - 27687203

AN - SCOPUS:84992034596

SN - 0735-1097

VL - 68

SP - 1601

EP - 1602

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 14

ER -